Menu Search
Equities

CSPC Pharmaceutical Group Ltd

1093:HKG

CSPC Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)4.69
  • Today's Change0.04 / 0.86%
  • Shares traded51.76m
  • 1 Year change-20.10%
  • Beta0.5666
Data delayed at least 15 minutes, as of Sep 19 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy9
Outperform12
Hold5
Sell1
Strong Sell1

Share price forecast in CNY

The 25 analysts offering 12 month price targets for CSPC Pharmaceutical Group Ltd have a median target of 8.42, with a high estimate of 12.92 and a low estimate of 4.30. The median estimate represents a 79.50% increase from the last price of 4.69.
High175.5%12.92
Med79.5%8.42
Low-8.3%4.30

Dividends in CNY

In 2023, CSPC Pharmaceutical Group Ltd reported a dividend of 0.25 CNY, which represents a 37.22% increase over last year. The 14 analysts covering the company expect dividends of 0.21 CNY for the upcoming fiscal year, a decrease of 17.49%.
Div growth (TTM)37.22%
More ▼

Earnings history & estimates in CNY

On Aug 21, 2024, CSPC Pharmaceutical Group Ltd reported 2nd quarter 2024 earnings of 0.119 per share.
The next earnings announcement is expected on Nov 28, 2024.
Average growth rate-1.60%
CSPC Pharmaceutical Group Ltd reported annual 2023 earnings of 0.495 per share on Mar 20, 2024.
Average growth rate+13.09%
More ▼

Revenue history & estimates in CNY

CSPC Pharmaceutical Group Limited had 2nd quarter 2024 revenues of 7.30bn. This missed the 8.54bn consensus estimate of the 3 analysts following the company. This was 9.33% below the prior year's 2nd quarter results.
Average growth rate-1.47%
CSPC Pharmaceutical Group Limited had revenues for the full year 2023 of 31.45bn. This was 1.66% above the prior year's results.
Average growth rate+9.31%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.